Amneal Pharmaceuticals, Inc. Class A Common Stock (NASDAQ:AMRX) is having a tough trading day, with shares down 2.90%. This decline comes despite recent positive news about the FDA approving its lanreotide injection, which is an important addition to its product lineup.
Investor takeaway: Investors should think about what Amneal's recent stock performance means and the challenges it faces, especially regarding its projected revenue growth and overall market sentiment.
Amneal's stock down 2.90% today
Advertisement
Amneal Pharmaceuticals, Inc. Class A Common Stock
AMRX.US
AMRX.US
Amneal Pharmaceuticals, Inc. Class A Common Stock
WealthAwesomeMarket cap
$6.52B
P/E
39.0x
52W high
$19.26
52W low
$9.49
1W change
+17.07%
Beta
1.24
Analyst Price Targets
Based on 4 analysts covering AMRX · as of Sep 21, 2026
Wall Street analysts forecast AMRX stock price to rise 9.1% over the next 12 months.
Consensus
Buy4.25 / 5.00
Avg. Target
C$22.00
+9.1% Upside
Previously C$21.33 on Sep 17, 2026
Current Price
C$20.16
Last close
Analyst Breakdown (4 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMRX's historical volatility
30-Day Vol
45.7%
Annualized
90-Day Vol
38.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$24.10
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$21.40 | C$18.28 – C$25.05 |
| 60 trading days | C$22.71 | C$18.17 – C$28.38 |
| 90 trading days | C$24.10 | C$18.34 – C$31.67 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
The drop reflects investor worries about Amneal's growth path amid mixed signals from its recent financial performance.
Bull case
The FDA's approval of the lanreotide injection could boost future revenue and strengthen Amneal's position in oncology treatments.
Bear case
Even with the FDA approval, analysts are doubtful about Amneal's growth potential. They point to slow revenue growth and a lack of improvements in profitability as concerns.
Recent Developments
Amneal recently announced the FDA's approval of its lanreotide injection, which is expected to enhance its offerings in the oncology sector. This product is vital for treating conditions like acromegaly and neuroendocrine tumors, and the company plans to use its in-house production capabilities for immediate market supply.
Advertisement
Market Sentiment and Analyst Opinions
Despite the good news about FDA approval, analysts are worried about Amneal's growth potential. The company is projected to grow revenue by only 3.3% over the next year, and its earnings per share (EPS) growth of 4.8% over the last five years suggests it may have trouble keeping investors interested. As a result, many analysts are advising caution regarding AMRX.
Looking Ahead
As Amneal navigates the complexities of the pharmaceutical market, investors need to keep a close eye on its performance metrics and market reactions. The recent drop in stock price may signal a reevaluation of the company's growth prospects, making it crucial for stakeholders to stay informed about upcoming financial reports and market trends.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
